Impact of the CD40-CD40L Dyad in Alzheimer's Disease

E-ISSN： 1996-3181|9|2|149-155

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.9, Iss.2, 2010-04, pp. : 149-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD40L - A Multipotent Molecule for Tumor Therapy

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 7, Iss. 1, 2007-03 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

Agonistic CD40 monoclonal antibody: `unexpected' effects

Inpharma, Vol. 1, Iss. 1243, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

CD40 levels predict benefit from abciximab in ACS

Inpharma, Vol. 1, Iss. 1380, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review

Current Cancer Drug Targets, Vol. 14, Iss. 7, 2014-09 ,pp. : 610-620

Bentham Science Publishers

Access to resources Recommend Favorite

Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis

Current Medicinal Chemistry, Vol. 14, Iss. 20, 2007-08 ,pp. : 2170-2180

Bentham Science Publishers

Access to resources Recommend Favorite